



## Inflammation, Immunity, and Cancer Progression

Guest Editors:

### Dr. Deepak Parashar

Division of Hematology & Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA

### Dr. Vivek K. Kashyap

Department of Immunology and Microbiology, South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, Edinburg, TX, USA

### Dr. Subhash Tripathi

Seattle Children's Research Institute, Seattle, CA, USA

Deadline for manuscript submissions:

**closed (31 May 2024)**

### Message from the Guest Editors

Chronic inflammation plays a significant role in cancer initiation, progression, metastasis, and chemoresistance. Additionally, cancer-related inflammation is the seventh hallmark of cancer and is associated with genetic instability. Genomic and epigenomic mechanisms are essential to establishing cellular programs in cancer and immune cells. The dysregulation of these mechanisms contributes to tumor growth.

This Special Issue will highlight the latest experimental advances and technical developments in genomics and epigenomics, gene editing, gene delivery, and therapeutic approaches for studying immune regulation in immune-mediated diseases, including autoimmunity and cancer.

Manuscript submissions presenting outstanding contributions to cancer and immunity fields, including, but not limited to, the following topics:

Inflammation in cancer immunity;  
Transcriptional and epigenetic regulations in cancer cells and immune cell differentiation and development;  
Transcriptomics and epigenomics of immune-mediated diseases;  
Immunometabolism;  
Pharmacogenomic of diseases;  
Integration of Bioinformatics Data.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)